Updated:
Decoy Therapeutics
Decoy Therapeutics develops MIT-spun peptide antivirals that mimic host-cell receptors to trap influenza and other respiratory viruses before they infect.
Decoy Therapeutics
Decoy Therapeutics engineers peptide therapeutics designed to intercept viruses before they can infect host cells. The company's foundational work originated at MIT, where research teams developed a computationally designed peptide that mimics the sialic acid receptors influenza viruses use to attach to lung cells. When delivered intranasally, this molecular decoy binds to the viral hemagglutinin protein, neutralizing the pathogen before infection takes hold. The firm's lead program targets pandemic and seasonal influenza, including both H1N1 and H5N1 strains that pose constant pandemic threats. Preclinical studies indicate the decoy construct maintains efficacy across viral mutations that typically erode the performance of strain-specific vaccines. Secondary targets include SARS-CoV-2 and other respiratory viruses that share similar attachment mechanisms via cell-surface glycans. The intranasal delivery route distinguishes Decoy's approach from systemic antivirals, offering a prophylactic or early-treatment modality that deploys directly at the point of viral entry. The company's core intellectual property was licensed from MIT laboratories and has been published in peer-reviewed journals including the Proceedings of the National Academy of Sciences. Decoy Therapeutics represents a specific thesis within computational protein design — applying rational engineering to anti-infectives rather than the oncology and rare-disease focus that dominates most therapeutic peptide companies. The firm operates at the intersection of structural biology, machine-learning-driven molecular simulation, and mucosal immunology. Human clinical trial timing has not been publicly disclosed. Structurally, Decoy Therapeutics is positioned as a standalone preclinical biotech company. Its differentiation lies in targeting a conserved viral mechanism — host-receptor binding — rather than chasing highly mutable viral surface proteins. A successful clinical outcome would expand the influenza countermeasure toolkit beyond vaccines and small-molecule neuraminidase inhibitors, which face resistance and strain-mismatch failures.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Sector focus
Frequently asked questions
What is the underlying scientific mechanism behind Decoy Therapeutics' platform?
Decoy's platform is built on computationally designed peptides that mimic sialic acid receptors found on human respiratory cells. Influenza viruses use hemagglutinin proteins on their surface to bind sialic acid and initiate infection. Decoy's peptide constructs act as decoys — binding tightly to hemagglutinin and blocking the virus from attaching to actual host cells. The decoy molecules are multivalent, presenting multiple receptor-mimicking sites simultaneously to increase binding avidity.
Which pathogens does Decoy Therapeutics target?
The firm's lead program targets pandemic and seasonal influenza strains, including H1N1 and the highly pathogenic avian H5N1 which has triggered pandemic concerns. Expansion targets include SARS-CoV-2 and other respiratory viruses whose entry mechanisms depend on binding to glycans on the surface of airway epithelial cells. The platform's logic applies broadly to any pathogen that initiates infection through host-cell glycan attachment.
How does Decoy's approach differ from a conventional flu vaccine or antiviral?
Vaccines train the immune system to recognize specific viral strains, but require accurate strain forecasting and are undermined by antigenic drift. Small-molecule antivirals like oseltamivir target viral replication machinery and face growing resistance issues. Decoy's decoy peptide mimics the host receptor that viruses require regardless of strain. Because viral mutations that reduce binding to the decoy would also reduce binding to host cells, the therapeutic maintains pressure across variants in a way that vaccines and direct antivirals may not.
What is the origin of Decoy Therapeutics' intellectual property?
The core IP was developed at MIT and published in top-tier journals including the Proceedings of the National Academy of Sciences. The research emerged from laboratories focused on computational protein design and respiratory immunology. Decoy Therapeutics licensed the foundational technology from MIT.
How is Decoy Therapeutics' product administered and what stage of development is it in?
The therapeutic is administered intranasally — directly into the nasal passage — targeting the upper respiratory tract where many respiratory viruses first establish infection. This contrasts with systemic oral or intravenous antivirals. Decoy Therapeutics remains preclinical as of the latest publicly available information; human clinical trial timelines have not been publicly disclosed.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: